About 66% of patients with primary liver cancer in China have concomitant hepatitis B virus infection. The trilogy of liver disease is commonly referred to as hepatitis, cirrhosis, and liver cancer, and the development of these trilogies is closely related.
Liver cancer: a malignant progression of cirrhosis and hepatitis
Many patients with hepatitis B and cirrhosis, due to improper or untimely treatment, as well as improper medication, poor lifestyle habits, and other factors, cause patients to progress malignantly, and their disease can easily deteriorate into liver cancer.
Cirrhosis: preventing complications of cirrhosis
Cirrhosis is generally irreversible, so it is important to prevent complications of cirrhosis while treating liver cancer, and to enhance symptomatic treatment such as liver-protective therapy and support.
Hepatitis: antiviral therapy
Patients with hepatitis B virus actively replicating liver cancer are treated with antiviral therapy in an effort to reduce the recurrence rate of hepatitis B-associated liver cancer and improve their survival. Antiviral therapy may help improve residual hepatocyte function while reducing the risk of recurrence of hepatocellular carcinoma and liver failure.